Paper36764323
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA and 18 others. Lancet Haematol, 2023. Cited by 102 papers, by iCite.
Cite this record
ConductScience Library. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Papers, record 36764323. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36764323
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Myelodysplastic Syndromes | Major topic |
| Humans | |
| NK Cell Lectin-Like Receptor Subfamily K | |
| Immunotherapy, Adoptive | |
| Cytokine Release Syndrome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 36764324 | Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome. | https://conductscience.org/library/papers/36764324 |
Source PubMed
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42801642 | A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42801642 | PubMed |
| 42681647 | A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42681647 | PubMed |
| 42645167 | Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies. | Cells | 2026 | https://conductscience.org/library/papers/42645167 | PubMed |
| 42575882 | CAR T cell therapy beyond cancer: current status, challenges and future prospects. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42575882 | PubMed |
| 42528842 | Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia. | Front Immunol | 2026 | https://conductscience.org/library/papers/42528842 | PubMed |
| 42519395 | Pediatric AML CAR T cell therapy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42519395 | PubMed |
| 42460416 | Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42460416 | PubMed |
| 42399624 | CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/42399624 | PubMed |
| 42380095 | Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42380095 | PubMed |
| 42241897 | Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors. | Cytotherapy | 2026 | https://conductscience.org/library/papers/42241897 | PubMed |
| 42180870 | Targeting the MICA/B-NKG2D axis in cancer: from molecular structure to immunotherapeutic strategies-a narrative review. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180870 | PubMed |
| 42034501 | Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure. | Blood Rev | 2026 | https://conductscience.org/library/papers/42034501 | PubMed |
| 42033215 | Advances in natural killer cell immunotherapy for hematologic malignancies. | Cancer Biol Ther | 2026 | https://conductscience.org/library/papers/42033215 | PubMed |
| 41802812 | Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41802812 | PubMed |
| 41800605 | Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation. | Ann Med | 2026 | https://conductscience.org/library/papers/41800605 | PubMed |
| 41799370 | Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy. | Immunooncol Technol | 2026 | https://conductscience.org/library/papers/41799370 | PubMed |
| 41622937 | Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions. | Ann Med | 2026 | https://conductscience.org/library/papers/41622937 | PubMed |
| 41578095 | The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/41578095 | PubMed |
| 41521321 | Molecularly targeted therapy and immunotherapy in leukemias. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/41521321 | PubMed |
| 41490616 | [Research progress of the ULBP-NKG2D axis in autoimmune diseases]. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2026 | https://conductscience.org/library/papers/41490616 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KLRK1 | 22914 | PubTator's text mining | https://conductscience.org/library/genes/22914 | NCBI Gene |
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36764323
GET https://conductscience.org/api/papers/v1/36764323/cited_by?page=2